Clinical trials: Healthy Men
Healthy
A Study in Healthy Men to Test How Different Doses of BI 3031185 Are Tolerated and How Food Influences the Amount of BI 3031185 in the Blood
This trial starts the clinical development of BI 3031185. The single rising dose (SRD) part of the trial investigates safety, tolerability, and pharmacokinetics of a range of single doses of BI 3031185 as basis for further…
- Trial name
- NCT06255340
- Testing
- BI 3031185
- Where
- Germany
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy Aging
An Open Label Study to Assess the Effect of Euryco-10® Oral Dietary Supplement in Senior Men
To evaluate the effect and support the tolerance of orally ingested formulation containing Eurycoma longifolia dietary supplement (Euryco-10) on a cohort of senior men.
- Trial name
- NCT04584918
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Innovus Pharmaceuticals, Inc.
Nutritional Intervention
Assessing Fermentability of a Dietary Fiber
The objective of this study is to provide evidence for its fermentability of a dietary fiber and to collect information regarding potential health opportunities for glucose control as well as tolerability when being consumed over…
- Trial name
- FCHO (NCT01497249)
- Testing
- A dietary fiber (FCHO)
- Where
- United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Clinical Nutrition Research Center, Illinois Institute of Technology
Healthy
A Relative Bioavailability Study of Bupropion Sustained Release 150 mg Tablets Under Fasting Conditions
The purpose of this study is to compare the rate and extent of absorption of Abrika Bupropion 150 mg sustained release tablet to that of Wellbutrin SR sustained release tablet after a single, one-tablet dose in fasted subjects.
- Trial name
- NCT00865111
- Testing
- Bupropion 150 mg Extended-Released Tablet, single dose, Wellbutrin SR® 150 mg Sustained-Release Tablet, single dose
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Actavis Inc.
Healthy
A Study to Test How Well Different Doses of BI 1584862 Are Tolerated by Healthy Men
The main objectives of this trial are to investigate safety, tolerability, and pharmacokinetics of BI 1584862 in healthy male subjects following administration of multiple rising doses.
- Trial name
- NCT06006598
- Testing
- BI 1584862, midazolam
- Where
- Germany
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy
A Study in Healthy Men to Test How BI 456906 is Processed in the Body
This trial is intended to examine the basic pharmacokinetics of BI 456906 and total [14C]-radioactivity, including mass balance, excretion pathways and metabolism following a single subcutaneous (SC) dose of BI 456906 (C-14) in…
- Trial name
- NCT05421338
- Testing
- BI 456906 (C-14)
- Where
- Netherlands
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy
Drug-Drug Interaction Study: ASP2151 and Montelukast
CYP2C8 is involved in the metabolism of many drugs. So, it is important to assess in vivo the inhibitory effect of ASP2151 on that enzyme to determine any possible drug interactions.
- Trial name
- NCT02321748
- Testing
- Montelukast, ASP2151
- Where
- United Kingdom
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Maruho Europe Limited
Healthy Participants
A Study Investigating the Movement of Lu AF28996 Into, Through, and Out of the Body of Healthy Men
The main goal of this study is to learn about how Lu AF28996 moves into, through, and out of the body after a single dose is given to healthy male participants.
- Trial name
- NCT06337110
- Testing
- Lu AF28996
- Where
- United Kingdom
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- H. Lundbeck A/S
Healthy
A Study in Healthy Men to Test How BI 690517 is Taken up and Handled by the Body
The trial is intended to investigate the basic pharmacokinetics, excretion pathways and metabolism of BI 690517 and its metabolites.
- Trial name
- NCT05515588
- Testing
- BI 690517 (C-14), BI 690517
- Where
- Netherlands
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Weight Loss
Effect of Transform Burn on Weight Loss
This study was undertaken to explore the effects of a Thermogenic Composition (TC) composed of dihydrocapsiate, red pepper (Capsicum annuum) fruit extract, citrus (Citrus spp) peel extract, coleus (Coleus forskholi) root extract…
- Trial name
- Transform (NCT06092840)
- Testing
- Transform Burn
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- 4Life Research, LLC
Postmenopausal, Osteopenia
A Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Romosozumab (AMG 785)
The primary objective of this study was to assess the safety, tolerability, and immunogenicity potential of romosozumab following multiple subcutaneous (SC) administrations in healthy men and postmenopausal women with low bone…
- Trial name
- NCT01825785
- Testing
- Romosozumab
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Amgen
Healthy Men
A Randomized, Double-blind, Single-dose, Two-arm Parallel Study to Compare the Pharmacokinetics and Safety of BAT1806 Prefilled Subcutaneous Injection With RoActemra® in Healthy Chinese Male Subjects
This is a randomized, double-blind, single-dose, two-arm parallel study to compare the pharmacokinetics, safety and immunogenicity of BAT1806 prefilled subcutaneous injection with RoActemra® (from EU) in healthy male subjects.
- Trial name
- NCT05968508
- Testing
- BAT1806 prefilled subcutaneous injection/RoActemra® (from EU)
- Where
- China
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Bio-Thera Solutions
Healthy
A Study in Healthy Men to Test How Different Doses of BI 1595043 Are Tolerated
The main objectives of this trial are to investigate safety, tolerability and pharmacokinetics (PK) of BI 1595043 in healthy male subjects following oral administration of single rising doses.
- Trial name
- NCT04439838
- Testing
- BI 1595043
- Where
- Belgium
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy
Bioequivalence Study of Zonisamide Capsules 100 mg of Dr.Reddy's Laboratories Limited Under Fasting Conditions
The objective of this study was to compare the rate and extent of absorption of Dr. Reddy's Zonisamide 100 mg Capsule to that of Zonegran® 100 mg Capsule after a single, one-capsule dose in fasted subjects.
- Trial name
- NCT01161966
- Testing
- Zonisamide, Zonegran
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Dr. Reddy's Laboratories Limited
Healthy
A Study in Healthy Men to Test How BI 765080 is Taken up in the Body When Given as an Injection Under the Skin Compared With an Infusion Into the Vein
A study in healthy man to investigate the absolute bioavailability of 100mg BI 765080, once administered as subcutaneous (SC) injection and once administered as intravenous infusion.
- Trial name
- NCT05075772
- Testing
- BI 765080
- Where
- Belgium
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy
A Study in Healthy Men to Test How Well Different Doses of BI 1569912 Are Tolerated
The main objectives of this trial are to investigate (1) safety, tolerability, pharmacokinetics and pharmacodynamics following multiple rising doses of BI 1569912; (2) tolerability of BI 1569912 in an up-titrating dosing scheme.
- Trial name
- NCT04978506
- Testing
- BI 1569912
- Where
- Germany
- Volunteers
- 83 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy
A Study in Healthy Men to Compare Two Different Oral Formulations of BI 1810631 and to Test How Food or Rabeprazole Influence the Amount of BI 1810631 in the Blood
BI 1810631 trial formulation 1 (TF1) is currently used in clinical trials, but is planned to be replaced by another formulation (principle) in future clinical trials and on the market.
- Trial name
- NCT05380947
- Testing
- BI 1810631 - trial formulation 1 (TF1), BI 1810631 - new formulation (NF), Rabeprazole sodium
- Where
- Germany
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy
This Study in Healthy Men Tests How the Body Takes up BI 1467335
The primary objective of this trial is to investigate the absolute bioavailability of BI 1467335 with an intravenous microdose formulation containing labelled [C-14] BI 1467335 and an unlabelled oral tablet formulation of BI…
- Trial name
- NCT03483506
- Testing
- BI 1467335, BI 1467335 (C-14) intravenous solution
- Where
- Netherlands
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy
A Study in Healthy Men to Test Whether BI 425809 Influences the Amount of Midazolam in the Blood
In order to assess the potential impact of steady state BI 425809 on CYP3A clinically, the effect of BI 425809 on the midazolam pharmacokinetics will be evaluated. Midazolam is a recommended substrate of CYP3A4.
- Trial name
- NCT05258110
- Testing
- midazolam, iclepertin (BI 425809)
- Where
- Germany
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy Volunteers, Atherosclerotic Cardiovascular Disease
A Research Study Looking at How the Medicine NNC0385-0434 Works in the Body of Healthy Japanese Men
The aim of this study is to look at how the study medicine works in the body and how it is removed from the body. We are testing the study medicine to make a medicine that can help people lower their cholesterol level.
- Trial name
- NCT05003440
- Testing
- NNC0385-0434
- Where
- Japan
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S